Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2011
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistanceMegan H Powdrill, Egor P Tchesnokov, Robert A Kozak, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2019
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/IKristen Andreatta, Madeleine Willkom, Ross Martin, et al.
Journal of Medical Virology|October 7, 2024
High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherenceKristen Andreatta, Michelle L D'Antoni, Silvia Chang, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2019
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 WeeksRima K Acosta, Madeleine Willkom, Ross Martin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2016
Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based TherapiesChristoph Sarrazin, Vasily Isakov, Evguenia S Svarovskaia, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2012
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatmentSeverine Margeridon-Thermet, Evguenia S Svarovskaia, Farbod Babrzadeh, et al.
Viruses|February 27, 2026
Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025Lauren Rodriguez, Jiani Li, Dong Han, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical TrialsBrian Moldt, Aiyappa Parvangada, Ross Martin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2024
Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trialWin Min Han, Sunil Solomon, Laura Smeaton, et al.
Antiviral Research|December 31, 2025
SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19Lauren Rodriguez, Yu Hu, Jiani Li, et al.
Pageof 8